Teva Pharmaceutical Industries annual debt-to-ebitda ratio
2008
2009
2010
2011
2012
2013
2016
2018
2019
2021
2023
2024
2025
Teva Pharmaceutical Industries Debt-to-EBITDA Ratio Growth & History (TEVA)
Teva Pharmaceutical Industries's debt-to-ebitda ratio was 0.71 for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.71 | −2.18 | −75.43% |
| 2024 | 2024-12-31 | 2.89 | 1.56 | +116.32% |
| 2023 | 2023-12-31 | 1.34 | — | — |
| 2021 | 2021-12-31 | 0.65 | — | — |
| 2019 | 2019-12-31 | 2.29 | −8.52 | −78.83% |
| 2018 | 2018-12-31 | 10.81 | — | — |
| 2016 | 2016-12-31 | 8.85 | — | — |
| 2013 | 2013-12-31 | 3.40 | −0.21 | −5.82% |
| 2012 | 2012-12-31 | 3.61 | 0.89 | +32.53% |
| 2011 | 2011-12-31 | 2.73 | 2.43 | +814.96% |
| 2010 | 2010-12-31 | 0.30 | −0.15 | −33.10% |
| 2009 | 2009-12-31 | 0.45 | −2.45 | −84.59% |
| 2008 | 2008-12-31 | 2.89 | — | — |
Teva Pharmaceutical Industries quarterly debt-to-ebitda ratio
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.16
Q1.17
Q4.18
Q4.19
Q1.20
Q2.20
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q2.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.85 | 1.45 | +365.53% |
| Q1 2026 | 2026-03-31 | 0.88 | 0.40 | +81.80% |
| Q4 2025 | 2025-12-31 | 0.71 | −2.18 | −75.43% |
| Q3 2025 | 2025-09-30 | 0.11 | −1.76 | −94.22% |
| Q2 2025 | 2025-06-30 | 0.40 | −0.82 | −67.33% |
| Q1 2025 | 2025-03-31 | 0.48 | −2.00 | −80.53% |
| Q4 2024 | 2024-12-31 | 2.89 | 1.56 | +116.32% |
| Q3 2024 | 2024-09-30 | 1.87 | — | — |
| Q2 2024 | 2024-06-30 | 1.21 | −48.11 | −97.54% |
| Q1 2024 | 2024-03-31 | 2.49 | — | — |
| Q4 2023 | 2023-12-31 | 1.34 | — | — |
| Q2 2023 | 2023-06-30 | 49.32 | 43.35 | +725.92% |
| Q3 2022 | 2022-09-30 | 21.84 | 20.93 | +2304.12% |
| Q2 2022 | 2022-06-30 | 5.97 | — | — |
| Q1 2022 | 2022-03-31 | 1.34 | — | — |
| Q4 2021 | 2021-12-31 | 0.65 | — | — |
| Q3 2021 | 2021-09-30 | 0.91 | — | — |
| Q2 2020 | 2020-06-30 | 1.01 | — | — |
| Q1 2020 | 2020-03-31 | 1.58 | — | — |
| Q4 2019 | 2019-12-31 | 2.29 | −8.52 | −78.83% |
| Q4 2018 | 2018-12-31 | 10.81 | — | — |
| Q1 2017 | 2017-03-31 | 9.17 | — | — |
| Q4 2016 | 2016-12-31 | 8.85 | — | — |
| Q3 2014 | 2014-09-30 | 0.36 | −0.48 | −57.62% |
| Q2 2014 | 2014-06-30 | 0.42 | −0.76 | −64.47% |
| Q1 2014 | 2014-03-31 | 0.46 | −0.27 | −37.56% |
| Q4 2013 | 2013-12-31 | 3.40 | −0.21 | −5.82% |
| Q3 2013 | 2013-09-30 | 0.84 | 0.70 | +508.07% |
| Q2 2013 | 2013-06-30 | 1.18 | 1.00 | +571.10% |
| Q1 2013 | 2013-03-31 | 0.73 | −0.12 | −14.49% |
| Q4 2012 | 2012-12-31 | 3.61 | 0.89 | +32.53% |
| Q3 2012 | 2012-09-30 | 0.14 | −0.63 | −82.07% |
| Q2 2012 | 2012-06-30 | 0.18 | −0.26 | −59.67% |
| Q1 2012 | 2012-03-31 | 0.85 | 0.58 | +212.64% |
| Q4 2011 | 2011-12-31 | 2.73 | 2.43 | +814.96% |
| Q3 2011 | 2011-09-30 | 0.77 | 0.53 | +216.46% |
| Q2 2011 | 2011-06-30 | 0.44 | −0.05 | −10.65% |
| Q1 2011 | 2011-03-31 | 0.27 | −0.28 | −50.19% |
| Q4 2010 | 2010-12-31 | 0.30 | −0.15 | −33.10% |
| Q3 2010 | 2010-09-30 | 0.24 | −0.73 | −75.04% |
| Q2 2010 | 2010-06-30 | 0.49 | −0.88 | −64.44% |
| Q1 2010 | 2010-03-31 | 0.55 | −1.79 | −76.51% |
| Q4 2009 | 2009-12-31 | 0.45 | −2.45 | −84.59% |
| Q3 2009 | 2009-09-30 | 0.98 | — | — |
| Q2 2009 | 2009-06-30 | 1.37 | — | — |
| Q1 2009 | 2009-03-31 | 2.33 | — | — |
| Q4 2008 | 2008-12-31 | 2.89 | — | — |
Teva Pharmaceutical Industries debt-to-ebitda ratio trends
Between the periods ended 2008-12-31 and 2025-12-31, Teva Pharmaceutical Industries's debt-to-ebitda ratio decreased from 2.89 to 0.71, a change of −2.18. The latest reported quarter, Q2 2026, shows 1.85.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗